EP Patent

EP3505519B1 — Pyridinamine-substituted heterotricyclo compounds, preparation thereof, and use in medicines

Assigned to Yangtze River Pharmaceutical Group Co Ltd · Expires 2022-01-05 · 4y expired

What this patent protects

Patent listed against trilaciclib-dihydrochloride.

Drugs covered by this patent

trilaciclib-dihydrochloride (TRILACICLIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: EP3505519B1
Jurisdiction: EP
Classification: —
Expires: 2022-01-05
Drug substance claim: No
Drug product claim: No
Assignee: Yangtze River Pharmaceutical Group Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.